IMR Press / FBE / Volume 5 / Issue 2 / DOI: 10.2741/E646

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Assessment criteria for compensation of occupational bladder cancer

Show Less
1 Urological practice, St. Augustin, Germany
2 Department of Urology, Klinikum Leverkusen, Leverkusen, Germany
3 Department of Urology, Johannesbad Fachklinik, Bad Fussing, Germany
4 Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany

*Author to whom correspondence should be addressed.


Front. Biosci. (Elite Ed) 2013, 5(2), 653–661;
Published: 1 January 2013

In Germany, more than 100 bladder tumor cases are annually recognized as occupational disease and compensated, given that medical experts regard exposure to carcinogenic aromatic amines as a likely cause of cancer. The amount of compensation is initially based on the tumor staging and grading at the time of initial diagnosis (“basic MdE”) [MdE – reduction of earning capacity] and is adapted after a recurrence-free period of 2 and 5 years, respectively. In the event of treatment or tumor-related secondary conditions, the monthly compensation increases based on the severity of the objectified functional disorder. In the following article, medical experts specializing in this field provide a complete list of all known disorders, including treatment-related loss of a kidney or erectile dysfunction. In addition, the weighting of medical criteria in the assessment and calculation of the compensation is analyzed in greater detail. Since the given criteria are based on comprehensible experiences of urologists with their patients, they also provide medical experts in other countries with valuable points of reference for the calculation of the compensation.

Bladder cancer
Occupational disease
Aromatic Amines
Back to top